name: 'chromosomal-instability-agent'
description: 'AI-powered analysis of chromosomal instability (CIN) signatures for cancer prognosis, immunotherapy response prediction, and therapeutic vulnerability identification.'
measurable_outcome: Execute skill workflow successfully with valid output within 15 minutes.
allowed-tools:
- read_file
- run_shell_command
Chromosomal Instability Agent
The Chromosomal Instability Agent analyzes CIN signatures to predict cancer prognosis, immunotherapy response, and therapeutic vulnerabilities. It integrates copy number alterations, aneuploidy scores, and CIN-related gene expression for comprehensive genomic instability assessment.
When to Use This Skill
- When assessing tumor aneuploidy and chromosomal instability levels.
- To predict prognosis based on CIN signatures.
- For identifying tumors vulnerable to CIN-targeted therapies (PARP, ATR, WEE1).
- When analyzing immune evasion mechanisms related to CIN.
- To stratify patients for immunotherapy based on CIN status.
Core Capabilities
CIN Scoring: Calculate comprehensive CIN scores from copy number data.
Aneuploidy Quantification: Measure arm-level and focal copy number alterations.
CIN Gene Expression: Analyze CIN70 and other transcriptional signatures.
Immune Correlation: Assess CIN-immune microenvironment relationships.
Therapeutic Vulnerability: Identify CIN-targeted treatment options.
Prognostic Modeling: Predict outcomes based on CIN signatures.
CIN Metrics
| Metric |
Calculation |
Interpretation |
| Aneuploidy score |
Arm-level alterations |
Chromosome-level CIN |
| SCNA burden |
Total CNV alterations |
Overall instability |
| Weighted GII |
Fraction altered genome |
Focal vs broad changes |
| CIN70 |
70-gene signature |
Transcriptional CIN |
| WGII |
Weighted genome instability |
Comprehensive score |
CIN70 Signature Genes
Core genes reflecting CIN phenotype:
- Mitotic checkpoint: BUB1, BUBR1, MAD2L1
- Kinetochore: CENPA, CENPF, NDC80
- DNA replication: MCM2-7, ORC1
- Cell cycle: CCNB1, CCNB2, CDK1, PLK1
- Chromosome segregation: AURKB, KIF2C, KIF11
Workflow
Input: Copy number data (segments), gene expression, mutation data.
CNV Analysis: Calculate arm-level and focal alterations.
Signature Scoring: Compute CIN70 and other transcriptional signatures.
Integration: Combine DNA and RNA-based CIN metrics.
Immune Analysis: Correlate CIN with TME composition.
Vulnerability Assessment: Identify targetable dependencies.
Output: CIN scores, prognosis, treatment recommendations.
Example Usage
User: "Analyze chromosomal instability in this breast cancer sample and identify treatment vulnerabilities."
Agent Action:
python3 Skills/Oncology/Chromosomal_Instability_Agent/cin_analyzer.py \
--cnv_segments tumor_cnv.tsv \
--expression rnaseq_tpm.tsv \
--mutations somatic.maf \
--tumor_type breast_cancer \
--signatures cin70,cin25 \
--output cin_report/
CIN and Immune Evasion
High CIN Associates With:
- Reduced immune infiltration
- Lower checkpoint inhibitor response
- Increased immune evasion
- cGAS-STING activation (paradoxical)
Mechanisms:
- Loss of tumor suppressors on chromosome arms
- Chronic inflammatory signaling
- Aneuploidy-induced stress responses
- Subclonal diversification
Therapeutic Vulnerabilities
| Target |
Agents |
CIN Context |
| PARP |
Olaparib, etc. |
High CIN + HRD |
| ATR |
Berzosertib |
Replication stress |
| WEE1 |
Adavosertib |
G2/M dependency |
| CHK1 |
Prexasertib |
Cell cycle checkpoint |
| KIF11 |
Ispinesib |
Mitotic dependency |
| Aurora kinases |
Alisertib |
Mitotic errors |
CIN-Based Patient Stratification
| CIN Level |
Prognosis |
ICI Response |
Alternative Therapy |
| Low |
Better |
Better |
Standard care |
| Intermediate |
Variable |
Variable |
Combination therapy |
| High |
Poor |
Poor |
CIN-targeted agents |
| Extreme |
Very poor |
Immune desert |
Chemotherapy |
AI/ML Components
CIN Score Prediction:
- Random forest on CNV features
- Expression-based CIN inference
- Multi-modal integration
Prognosis Modeling:
- Cox regression with CIN features
- Cancer-type specific models
- Integration with clinical variables
Therapeutic Matching:
- GDSC/CCLE drug sensitivity
- CIN-drug response correlations
- Combination predictions
Pan-Cancer CIN Patterns
| Cancer Type |
Typical CIN Level |
Driver Events |
| Ovarian HGSOC |
Very high |
TP53, BRCA |
| Triple-neg breast |
High |
TP53, PI3K |
| Colorectal MSS |
Moderate-high |
APC, TP53 |
| Colorectal MSI |
Low |
MMR deficiency |
| Thyroid (PTC) |
Low |
BRAF, RAS |
| Melanoma |
Moderate |
BRAF, NRAS |
Prerequisites
- Python 3.10+
- GISTIC2 or similar for CNV analysis
- Gene signature databases
- Survival analysis packages
Related Skills
- HRD_Analysis_Agent - For HR-specific instability
- Pan_Cancer_MultiOmics_Agent - For pan-cancer context
- Tumor_Clonal_Evolution_Agent - For evolutionary dynamics
Research Applications
- Biomarker Development: CIN as predictive marker
- Drug Development: CIN-targeted therapy trials
- Evolution Studies: Track CIN changes over time
- Resistance Mechanisms: CIN and drug resistance
Author
AI Group - Biomedical AI Platform
1---2name: chromosomal-instability-agent3description: <!--4---5<!--6# COPYRIGHT NOTICE7# This file is part of the "Universal Biomedical Skills" project.8# Copyright (c) 2026 MD BABU MIA, PhD <md.babu.mia@mssm.edu>9# All Rights Reserved.10#11# This code is proprietary and confidential.12# Unauthorized copying of this file, via any medium is strictly prohibited.13#14# Provenance: Authenticated by MD BABU MIA1516-->1718---19name: 'chromosomal-instability-agent'20description: 'AI-powered analysis of chromosomal instability (CIN) signatures for cancer prognosis, immunotherapy response prediction, and therapeutic vulnerability identification.'21measurable_outcome: Execute skill workflow successfully with valid output within 15 minutes.22allowed-tools:23 - read_file24 - run_shell_command25---262728# Chromosomal Instability Agent2930The **Chromosomal Instability Agent** analyzes CIN signatures to predict cancer prognosis, immunotherapy response, and therapeutic vulnerabilities. It integrates copy number alterations, aneuploidy scores, and CIN-related gene expression for comprehensive genomic instability assessment.3132## When to Use This Skill3334* When assessing tumor aneuploidy and chromosomal instability levels.35* To predict prognosis based on CIN signatures.36* For identifying tumors vulnerable to CIN-targeted therapies (PARP, ATR, WEE1).37* When analyzing immune evasion mechanisms related to CIN.38* To stratify patients for immunotherapy based on CIN status.3940## Core Capabilities41421. **CIN Scoring**: Calculate comprehensive CIN scores from copy number data.43442. **Aneuploidy Quantification**: Measure arm-level and focal copy number alterations.45463. **CIN Gene Expression**: Analyze CIN70 and other transcriptional signatures.47484. **Immune Correlation**: Assess CIN-immune microenvironment relationships.49505. **Therapeutic Vulnerability**: Identify CIN-targeted treatment options.51526. **Prognostic Modeling**: Predict outcomes based on CIN signatures.5354## CIN Metrics5556| Metric | Calculation | Interpretation |57|--------|-------------|----------------|58| Aneuploidy score | Arm-level alterations | Chromosome-level CIN |59| SCNA burden | Total CNV alterations | Overall instability |60| Weighted GII | Fraction altered genome | Focal vs broad changes |61| CIN70 | 70-gene signature | Transcriptional CIN |62| WGII | Weighted genome instability | Comprehensive score |6364## CIN70 Signature Genes6566Core genes reflecting CIN phenotype:67- Mitotic checkpoint: BUB1, BUBR1, MAD2L168- Kinetochore: CENPA, CENPF, NDC8069- DNA replication: MCM2-7, ORC170- Cell cycle: CCNB1, CCNB2, CDK1, PLK171- Chromosome segregation: AURKB, KIF2C, KIF117273## Workflow74751. **Input**: Copy number data (segments), gene expression, mutation data.76772. **CNV Analysis**: Calculate arm-level and focal alterations.78793. **Signature Scoring**: Compute CIN70 and other transcriptional signatures.80814. **Integration**: Combine DNA and RNA-based CIN metrics.82835. **Immune Analysis**: Correlate CIN with TME composition.84856. **Vulnerability Assessment**: Identify targetable dependencies.86877. **Output**: CIN scores, prognosis, treatment recommendations.8889## Example Usage9091**User**: "Analyze chromosomal instability in this breast cancer sample and identify treatment vulnerabilities."9293**Agent Action**:94```bash95python3 Skills/Oncology/Chromosomal_Instability_Agent/cin_analyzer.py \96 --cnv_segments tumor_cnv.tsv \97 --expression rnaseq_tpm.tsv \98 --mutations somatic.maf \99 --tumor_type breast_cancer \100 --signatures cin70,cin25 \101 --output cin_report/102```103104## CIN and Immune Evasion105106**High CIN Associates With**:107- Reduced immune infiltration108- Lower checkpoint inhibitor response109- Increased immune evasion110- cGAS-STING activation (paradoxical)111112**Mechanisms**:1131. Loss of tumor suppressors on chromosome arms1142. Chronic inflammatory signaling1153. Aneuploidy-induced stress responses1164. Subclonal diversification117118## Therapeutic Vulnerabilities119120| Target | Agents | CIN Context |121|--------|--------|-------------|122| PARP | Olaparib, etc. | High CIN + HRD |123| ATR | Berzosertib | Replication stress |124| WEE1 | Adavosertib | G2/M dependency |125| CHK1 | Prexasertib | Cell cycle checkpoint |126| KIF11 | Ispinesib | Mitotic dependency |127| Aurora kinases | Alisertib | Mitotic errors |128129## CIN-Based Patient Stratification130131| CIN Level | Prognosis | ICI Response | Alternative Therapy |132|-----------|-----------|--------------|---------------------|133| Low | Better | Better | Standard care |134| Intermediate | Variable | Variable | Combination therapy |135| High | Poor | Poor | CIN-targeted agents |136| Extreme | Very poor | Immune desert | Chemotherapy |137138## AI/ML Components139140**CIN Score Prediction**:141- Random forest on CNV features142- Expression-based CIN inference143- Multi-modal integration144145**Prognosis Modeling**:146- Cox regression with CIN features147- Cancer-type specific models148- Integration with clinical variables149150**Therapeutic Matching**:151- GDSC/CCLE drug sensitivity152- CIN-drug response correlations153- Combination predictions154155## Pan-Cancer CIN Patterns156157| Cancer Type | Typical CIN Level | Driver Events |158|-------------|-------------------|---------------|159| Ovarian HGSOC | Very high | TP53, BRCA |160| Triple-neg breast | High | TP53, PI3K |161| Colorectal MSS | Moderate-high | APC, TP53 |162| Colorectal MSI | Low | MMR deficiency |163| Thyroid (PTC) | Low | BRAF, RAS |164| Melanoma | Moderate | BRAF, NRAS |165166## Prerequisites167168* Python 3.10+169* GISTIC2 or similar for CNV analysis170* Gene signature databases171* Survival analysis packages172173## Related Skills174175* HRD_Analysis_Agent - For HR-specific instability176* Pan_Cancer_MultiOmics_Agent - For pan-cancer context177* Tumor_Clonal_Evolution_Agent - For evolutionary dynamics178179## Research Applications1801811. **Biomarker Development**: CIN as predictive marker1822. **Drug Development**: CIN-targeted therapy trials1833. **Evolution Studies**: Track CIN changes over time1844. **Resistance Mechanisms**: CIN and drug resistance185186## Author187188AI Group - Biomedical AI Platform189190191<!-- AUTHOR_SIGNATURE: 9a7f3c2e-MD-BABU-MIA-2026-MSSM-SECURE -->